Navigation Links
MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
Date:12/4/2008

'A Highly Efficient, Clinical Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity'

GAITHERSBURG, Md., Dec. 4 /PRNewswire/ --MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Joseph C. Fratantoni, MD, Vice President Medical Affairs and Clinical Development at MaxCyte, will give a presentation on a breakthrough approach to developing cancer therapies at the 50th ASH Annual Meeting to be held at the Moscone Center in San Francisco, December 6-9, 2008. Dr. Fratantoni's presentation is entitled, "A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity" and will be held during the Tumor Immunotherapy Poster II Session on Monday, December 8, 2008 at 5:30 PM - 7:30 PM in Moscone Center, Hall A (Poster Board no.: III-976).

The presentation will discuss how chimeric tumor-antigen receptor mRNA loaded peripheral blood mononuclear cells offer the potential to develop customizable, engineered outpatient transfusion medicine products for cancer therapies without the infrastructure and logistical challenges associated with development of traditional cellular therapy products. This represents a paradigm shift in current cancer therapy approaches and utilizes current transfusion medicine infrastructure present in any major hospital.

About MaxCyte

MaxCyte is the leader in providing clinical/commercial cell modification technologies and unparalleled expertise to the global leaders in cell-based therapies. MaxCyte's cell transfection technology platform

enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases.

MaxCyte's licenses its cell modification technology to companies developing cell-based therapies and sells instruments and disposables to leading biopharmaceutical companies for drug discovery. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of Chronic Lymphocytic Leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, MaxCyte's partner in Japan has commercially launched an immunotherapy cancer service. More than a dozen commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER). Building on its core technology and relationships, new opportunities are being pursued in the development of first-in-class targeted therapies for cancer, autoimmune, and infectious diseases. MaxCyte intends to develop these programs to the proof-of-concept stage and then enter into co-development agreements with biopharmaceutical companies.

For more information, visit http://www.maxcyte.com.


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
2. MaxCyte to Present at the BIO CEO & Investor Conference
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes ... and around the nation. What do they have in common? All have been affected ... compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... promoting to the US market its advanced highly customizable contact technology solutions. , ... TURNTAC®. These advanced technologies are ideal for a wide range of applications that ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers ... to residents in the Sacramento/Folsom region, is initiating a charity event to raise ... Another Choice Another Chance treatment center in Sacramento works to provide area teens ...
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a ... throughout the Five Boroughs, is launching a charity drive to raise funds that will ... traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the MCL, ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... KEY FINDINGS Patient warming ... reducing loss of blood during surgeries, lowering the ... recovery after surgeries, and decreasing risks of SSIs. ... convective warming system, surface warming systems, and intravascular ... stay at hospitals thus, lowering the healthcare costs ...
(Date:12/7/2016)... 7, 2016 Global Hospital Linen Supply and ... global hospital linen supply and management services market presents ... a global and regional level. The study provides historic ... between 2015 and 2024 based on revenue (US$ Bn). ... market along with their impact on demand during the ...
(Date:12/7/2016)... N.J. , Dec. 7, 2016  Palatin ... it has closed on a previously disclosed underwritten ... $16,500,000.  Canaccord Genuity acted as sole book-running manager, ... Chardan Capital Markets acted as co-manager for the ... approximately $15.4 million in net proceeds, allowing us ...
Breaking Medicine Technology: